Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2016, Article ID 8175957, 3 pages
http://dx.doi.org/10.1155/2016/8175957
Case Report

Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma

1Hôpital de la Tour Unite d’Oncologie-Hematologie, Meyrin, Switzerland
2Viollier Weintraub, Geneva, Switzerland

Received 6 June 2016; Revised 22 July 2016; Accepted 2 August 2016

Academic Editor: Akimichi Ohsaka

Copyright © 2016 Claudius Irlé and Jonathan Weintraub. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. M. Foss, P. L. Zinzani, J. M. Vose, R. D. Gascoyne, S. T. Rosen, and K. Tobinai, “Peripheral T-cell lymphoma,” Blood, vol. 117, no. 25, pp. 6756–6767, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. S. M. Horwitz, “Management of peripheral T-cell non-Hodgkin's lymphoma,” Current Opinion in Oncology, vol. 19, no. 5, pp. 438–443, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. F. M. Foss, K. R. Carson, L. Pinter-Brown et al., “Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): first detailed report of primary treatment,” Blood, vol. 120, no. 21, article 1614, 2012. View at Google Scholar
  4. J. Vose, J. Armitage, and D. Weisenburger, “International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4124–4130, 2008. View at Publisher · View at Google Scholar
  5. NCCN, NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas, vol. 3, NCCN, 2016.
  6. J. Tan, S. Cang, Y. Ma, R. L. Petrillo, and D. Liu, “Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents,” Journal of Hematology and Oncology, vol. 3, article 5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. E. Bolden, M. J. Peart, and R. W. Johnstone, “Anticancer activities of histone deacetylase inhibitors,” Nature Reviews Drug Discovery, vol. 5, no. 9, pp. 769–784, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. J. E. Bradner, N. West, M. L. Grachan et al., “Chemical phylogenetics of histone deacetylases,” Nature Chemical Biology, vol. 6, no. 3, pp. 238–243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. ISTODAX (romidepsin) [package insert], 2014.
  10. B. Coiffier, B. Pro, H. M. Prince et al., “Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy,” Journal of Clinical Oncology, vol. 30, no. 6, pp. 631–636, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Coiffier, B. Pro, H. M. Prince et al., “Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses,” Journal of Hematology and Oncology, vol. 7, no. 1, article 11, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Pro, S. M. Horwitz, H. M. Prince et al., “Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma,” Hematological Oncology, 2016. View at Publisher · View at Google Scholar